New Manufacturing Facility, Special Meeting Updates, Recognition, Technical Updates, and Clinical Data - Research Reports on Valeant, Allergan, Isis, Regeneron and Teva

NEW YORK, September 17, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Allergan Inc. (NYSE: AGN), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Teva Pharmaceutical Industries Limited (NYSE: TEVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6534-100free.

--
Valeant Pharmaceuticals International, Inc. Research Reports
On September 8, 2014, Valeant Pharmaceuticals International, Inc. (Valeant) announced the expansion of its Bausch + Lomb manufacturing facility in Rochester, New York, which will produce the Company's silicone hydrogel contact lens, Bausch + Lomb ULTRA. Valeant also reported the inauguration of solar array assembly at the company's Optics Center, which is expected to generate and supply electricity through the installation of 3,667 solar panels, helping to reduce the Rochester facility's carbon footprint by 800 tons of carbon dioxide emissions annually. Valeant's Chairman and CEO, J. Michael Pearson said, "Our Rochester Optics Center is a first in class manufacturing site for contact lens manufacturing and distribution, and with the new contact lens manufacturing lines, we will add much needed production capacity to supply both current and future demand." The full research reports on Valeant are available to download free of charge at:

http://www.analystsreview.com/Sep-17-2014/VRX/report.pdf

--
Allergan Inc. Research Reports
On September 11, 2014, Allergan Inc. (Allergan) released a statement after Pershing Square Capital Management, L.P. (Pershing Square) delivered additional requests from stockholders owning 1.5% of Allergan's shares to call a Special Meeting of Stockholders. The Company said that it will review these additional requests, in addition to the requests from stockholders owning 2.8% of Allergan's shares that were delivered on September 3, 2014. Following is an excerpt from Allergan's statement - "Allergan has already scheduled the Special Meeting for December 18, 2014. As such, the delivery of additional requests for the Special Meeting by Pershing Square is not a meaningful development. The lawsuit in California is seeking an order barring Valeant, Pershing Square, Mr. Ackman, and entities affiliated with them from voting shares that Allergan believes were acquired in violation of the federal securities laws, including insider trading. If Allergan's motion for a preliminary injunction is granted, it would prevent Valeant, Pershing Square, and Mr. Ackman from voting their shares at any meeting of stockholders." The full research reports on Allergan are available to download free of charge at:

http://www.analystsreview.com/Sep-17-2014/AGN/report.pdf

--
Isis Pharmaceuticals, Inc. Research Reports
On September 2, 2014, Isis Pharmaceuticals, Inc. (Isis) announced that data from three drugs in its lipid franchise were highlighted in four presentations at the 2014 European Society of Cardiology (ESC) Congress in Barcelona Spain. The Company's lipid franchise of antisense drugs, comprising one commercialized drug and several other drugs in clinical development, is designed to provide effective and safe therapeutic options to treat patients with lipid disorders. Data presented at the 2014 ESC included - a retrospective analysis of data from a long-term extension study of KYNAMRO® (mipomersen sodium) injection; an overall summary of the Phase 2 program for ISIS-APOCIIIRX; and data from the Phase 1 study of ISIS-APO(a)RX. The full research reports on Isis are available to download free of charge at:

http://www.analystsreview.com/Sep-17-2014/ISIS/report.pdf

--
Regeneron Pharmaceuticals, Inc. Research Reports
On September 12, 2014, the stock of Regeneron Pharmaceuticals, Inc. (Regeneron) fell 1.22% to end the trading session at $346.06. After opening at $349.41, the stock fluctuated in the range of $344.05 - $349.83. Shares in Regeneron have increased by 0.87% in the last one month, compared to the Nasdaq 100 index which rose 3.04% during that period. The full research reports on Regeneron are available to download free of charge at:

http://www.analystsreview.com/Sep-17-2014/REGN/report.pdf

--
Teva Pharmaceutical Industries Limited Research Reports
On September 12, 2014, Teva Pharmaceuticals Industries Limited (Teva) and Active Biotech jointly announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS), who were treated with laquinimod in Phase II, Phase III and open-label extension studies for two or more years. According to the Company, the pooled safety analysis of the Phase II LAQ/5063 and the Phase III ALLEGRO and BRAVO extension studies supports findings observed in the core studies where currently identified risks were observed within the first months of laquinimod treatment. "In this pooled analysis, laquinimod has shown to be safe for patients taking the treatment for two or more years, which supports the safety profile of laquinimod when used in a longer-term setting," said Professor Giancarlo Comi, Director of the Department of Neurology and Institute of Experimental Neurology at the San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Italy. The full research reports on Teva are available to download free of charge at:

http://www.analystsreview.com/Sep-17-2014/TEVA/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED